Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
Ready for the return of Belantamab Mafodotin? by Ajai Chari, MD from Professor of Medicine Director of Myeloma Program University of California San Francisco , and it's been added/updated in Multiple Myeloma Category
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Updates from American Society of Hematology 2022 Meeting: CAR-T Cells by Jeffrey Zonder,M.D. from Barbara Ann Karmanos Cancer Institute Wayne Sate University School of Medicine Detroit, MI. , and it's been added/updated in Multiple Myeloma Category
ASCO 2023 Highlights : Myeloma by Luciana Costa MD PhD from Marry and Bill Battle Professor in Multiple Myeloma, Director of Multiple Myeloma Program, University of Alabama, Birmingham, AL, and it's been added/updated in Multiple Myeloma Category
Updates from American Society of Hematology 2022 Meeting: Bispecifics by Peter Voorhees, MD from Chief of the Plasma Cell Disorders Division, Levine Cancer Institute, Charlotte, NC, and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Long-Term Follow-Up of the MonumenTAL-1 Trial
Managing Adverse Events with BCMA Therapy
Trials of bispecific antibodies in earlier treatment lines show promise.
The Significance of GPRC5D as a Target for Relapsed/Refractory Multiple Myeloma
53-year-old man with heavily pre-treated multiple myeloma, including T-cell therapy.
Dr. Lonial discusses findings from the CoMMpass Trial in multiple myeloma.
Clinical Insights on Patient Case and Treatment Pathway
Dr.Arnulf discusses managing tumor burden to improve PFS with Ide-Cel in relapsed/refractory myeloma
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
Ready for the return of Belantamab Mafodotin? by Ajai Chari, MD from Professor of Medicine Director of Myeloma Program University of California San Francisco , and it's been added/updated in Multiple Myeloma Category
Isatuximab:For Front-line Transplant Ineligible Patients by Adriana Rossi MD from Assistant Professor Director CAR-T and Stem Cell Transplant Clinical Program Mt Sinai Hospital New York , and it's been added/updated in Multiple Myeloma Category
Updates from American Society of Hematology 2022 Meeting: CAR-T Cells by Jeffrey Zonder,M.D. from Barbara Ann Karmanos Cancer Institute Wayne Sate University School of Medicine Detroit, MI. , and it's been added/updated in Multiple Myeloma Category
ASCO 2023 Highlights : Myeloma by Luciana Costa MD PhD from Marry and Bill Battle Professor in Multiple Myeloma, Director of Multiple Myeloma Program, University of Alabama, Birmingham, AL, and it's been added/updated in Multiple Myeloma Category
Updates from American Society of Hematology 2022 Meeting: Bispecifics by Peter Voorhees, MD from Chief of the Plasma Cell Disorders Division, Levine Cancer Institute, Charlotte, NC, and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Long-Term Follow-Up of the MonumenTAL-1 Trial
Managing Adverse Events with BCMA Therapy
Trials of bispecific antibodies in earlier treatment lines show promise.
The Significance of GPRC5D as a Target for Relapsed/Refractory Multiple Myeloma
53-year-old man with heavily pre-treated multiple myeloma, including T-cell therapy.
Dr. Lonial discusses findings from the CoMMpass Trial in multiple myeloma.
Clinical Insights on Patient Case and Treatment Pathway
Dr.Arnulf discusses managing tumor burden to improve PFS with Ide-Cel in relapsed/refractory myeloma
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
